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Abstract 
 To date, research examining the effects of comprehensive state mental health 
parity on the receipt of substance abuse treatment is limited. Comprehensive state 
mental health parity laws address the inequality between the receipt of treatment 
between mental health services and medical/surgical services more systematically than 
federally mandated mental health parity laws. The goal of comprehensive state parity 
laws is to reduce barriers in place that affect the receipt of substance abuse treatment. In 
this study, I sample twenty states in order to identify the treatment gap rate for 
substance use disorders in percentages and the per capita state expenditures for mental 
health treatment in average dollars per person. The treatment gap percentage is the ratio 
of the total number of individuals identified as needing, but not receiving treatment for 
substance use disorders within the last year divided by individuals identified as having a 
substance use disorder in the past year. The twenty states sampled included ten with 
comprehensive state mental health parity laws and ten states with the federally 
mandated mental health parity laws, the purpose of this sample is to identify if 
comprehensive state mental health parity resulted in a reduced treatment gap rate. The 
second measure is to identify if states with comprehensive mental health parity reflected 
an increase in expenditures for substance abuse treatment per person. The result of the 
research conducted did not find a significant difference for the substance use disorder 
treatment gap with the exception of the age group 12-17 year olds. Second, state 
expenditures per capita on substance abuse treatment was significant for states with 
more comprehensive state mental health parity laws. 
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Chapter 1: Introduction 
The previous barriers to treatment for substance use disorders has changed 
considerably since 2008. Two pivotal federally mandated changes occurred, the Mental 
Health Parity and Addiction Equity Act of 2008 (MHPAEA) and the Affordable Care 
Act of 2010 (ACA). Prior to both of these Acts, public and private insurers were not 
required to offer coverage benefits for substance use disorders equal to coverage 
benefits for other health conditions. These disparities were reflected in annual and 
lifetime dollar limits, financial requirements, and treatment limitations. After federal 
mental health parity laws went into effect insurers were required to offer equitable 
coverage for substance use disorders and other health benefits if the insurer offered any 
behavioral health coverage. In addition to the federal Acts that have contributed to 
mental health parity, certain states have passed state mental health parity laws 
exceeding the federal mandates. 
A current estimate of the treatment gap rate for individuals reporting symptoms 
of a substance use disorder but not receiving substance abuse treatment in the United 
States is greater than 93.0 percent for public, private, and uninsured individuals 
(Bouchery, Hardwood, Dilonardo, and Vandivort-Warren, 2012). Considering the 
significant treatment gap between individuals stating they have symptoms of a 
substance use disorder and those receiving any type of substance abuse treatment would 
suggest that the federally mandated Acts are not having a substantial impact on the 
receipt of substance abuse treatment. The barriers reported to receiving substance abuse 
treatment are access, financial, and personal or organizational familiarity with the 
federal mental health parity Acts. Mental health parity laws are in place to ensure 
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equitable treatment of mental health disorders compared to other health conditions, the 
substance abuse treatment gap rate of 93.0 percent does not reflect an effectiveness of 
any mental health parity laws. 
Several studies tracking expenditures on substance use disorders between 1992 
and 2012 document an increase in spending on substance use disorder treatment. This is 
reflected in the overall spending on substance use disorders nationally and by type of 
treatment: inpatient, outpatient, and pharmaceutical. The trend is a decrease in spending 
on inpatient treatment and an increase on spending on outpatient and pharmaceutical. 
The same studies note that overall spending on substance abuse treatment is 
considerably less than spending on other health conditions (Mark & Vandivort-Warren, 
2012, Mark & Coffey, 2004, and Mark, Levit, Yee, & Chow, 2014).  
Chapter 2: Literature Review 
Mental Health Parity and Equity Act 2008 
According to a 2014 National Survey on Drug Use and Health (NSDUH) by the 
Substance Abuse and Mental Health Services Administration (SAMHSA) (2016), 
approximately 18.1 percent of Americans over the age of 18 experience some form of 
mental illness. The same study revealed that 8.4 percent or 20.2 million adults reported 
a substance use disorder. It is important to understand the relationship between mental 
illness and substance use disorders. According to Cosci & Fava (2011), date obtained 
from the National Comorbidity Survey indicate that 41.0 to 65.5 percent of individuals 
who suffer from a lifetime substance use disorder are also diagnosed with a lifetime of a 
minimum of one other mental illness. Understanding the relationship between substance 
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use disorders and other mental illnesses is imperative to understanding the complexity 
of a substance use disorder. 
Mental health disorders involve deviations in thinking, mood, and behaviors. 
These behavioral irregularities also affect interpersonal relationships and decision-
making skills. However, mental health disorders are treatable and manageable. A 
substance use disorder is diagnosed when an individual experiences recurring use of 
alcohol or illicit/prescription drugs which creates significant impairment. Types of 
impairments caused by substance use disorders include health problems, disability, and 
failure to meet work, school, or home obligations. Types of treatment for substance use 
disorders include one or more of the following: individual and group counseling, 
inpatient and residential treatment, intensive outpatient treatment, partial hospitalization 
program, case or care management, medication, recovery support services, 12-step 
fellowship, and peer support (SAMHSA, 2016). 
The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) 
ensures that group health plans and issuers of health insurance policies provide 
equitable benefits compared to medical/surgical benefits (U.S. Department of Labor, 
2010). MHPAEA requires that financial obligations of copays, deductibles, and 
coinsurance are equal to these same type of financial obligations for medical/surgical 
coverage, treatment limitations (visit limits) must also be equal among both mental 
health coverage and medical/surgical coverage (U.S. Department of Labor, 2010). 
MHPAEA applies to both public and employer sponsored insurance plans (U.S. 
Department of Labor, 2010).  
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The MHPAEA is a federally mandated act that applies to all states within the 
United States. States have the option to pass legislative mandates addressing mental 
health parity that exceed the requirements of MHPAEA. The state mental health parity 
laws legislated that exceed the requirements of MHPAEA are considered 
comprehensive state mental health parity (National Alliance on Mental Illness (NAMI), 
2010). Comprehensive parity is defined as equal coverage of an extensive range of 
mental health conditions that includes substance use disorders, comprehensive parity 
does not allow for exemptions for private insurers conducting business within 
comprehensive parity states (NAMI, 2010). The comprehensive state parity laws 
attempt to address some of the loopholes of MHPAEA. 
 
Types of Health Insurance and the Affordable Care Act of 2010 
Public insurance coverage is a combination of federal and state funding, 
enrollment in public insurance coverage is dependent upon qualifications based on an 
individual’s limited income and resources (Centers for Medicare & Medicaid Services 
(CMS), 2016). After the final regulations issued in 2014 by the ACA of 2010, employer 
sponsored health plans are required to meet organizational and benefit minimums of 
coverage (Internal Revenue Service (IRS), 2016). According to the ACA, employers 
employing a minimum of 50 full-time individuals or part-time and full-time employees 
equaling 50 or more full-time individuals are subject to ACA guidelines (IRS, 2016). 
Benefits offered by employers meeting ACA guidelines are required to offer essential 
benefits as identified by CMS (2016). Individual health plans purchased on an 
individual basis that are not part of an employer sponsored health plan are required to 
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meet ACA standards of minimum required. Each health insurance plan is required to 
cover the following: ambulatory patient services, emergency services, hospitalizations, 
pregnancy/maternity/newborn care, mental and substance use disorder services, 
prescription drugs, rehabilitative services, laboratory services, prevention and wellness, 
pediatrics, birth control coverage, and breastfeeding coverage (CMS, 2016). 
Individual and employer sponsored health insurance plans are responsible for a 
fee structure that assigns a portion to the insurer and a portion to the patient, these 
portions combined are paid to the provider of the healthcare services, this combined 
payment is called cost-sharing (Blue Cross Blue Shield Network (BCBS), 2016). Cost 
sharing becomes a significant factor in the receipt of substance abuse treatment. 
Examples of cost sharing are deductibles, coinsurance, and copays (BCBS, 2016). A 
deductible is the portion the patient pays for services before the insurer begins to pay a 
contribution (BCBS, 2016). Coinsurance is the patient’s share of the cost of the services 
received figured as a percentage of the total allowable cost from the provider (BCBS, 
2016). A copay is a fixed amount the patient is responsible for based on the type of 
health related service received (BCBS, 2016). If cost sharing for substance abuse 
treatment is not equitable to the receipt of other health conditions financial barriers may 
contribute to an increased substance use treatment gap. 
Expenditures on Substance Use Disorders by Private Insurers 1992-2012 
and Projections through 2020 
Expenditures 1992 – 2001 
A study by Mark and Coffey (2004) examined trends in substance use disorder 
treatment financed through private insurance from 1992 to 2001. The findings reflect a 
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decline in spending on any substance abuse service including inpatient, outpatient, and 
pharmaceutical services. Examining each category independently, outpatient treatment 
dropped 5 percent during this time and in 2001 the mean spending per visit in real 
dollars dropped by one-third. The length of stay for inpatient treatment decreased by ten 
days while the rate of admission or readmission rate increased by 4.2 percent (Mark & 
Coffey, 2004). The spending per prescription by the patient increased by 90.5 percent in 
1992 and 271.1 percent in 2001 (Mark & Coffey, 2004). Overall spending on substance 
abuse treatment by private insurers decreased by 73.6 percent in nominal dollars. Cost 
sharing by the patient increased from 14.0 percent in 1992 to 19.0 percent in 2001 
(Mark & Coffey, 2004).  
Expenditures 2001 – 2009 
The overall expenditure for substance abuse treatment between 2001 and 2009 
averaged $18 per privately insured patient, spending on substance abuse treatment per 
enrolled member increased from 9.81 percent in 2001 to 17.86 percent in 2009 (Mark & 
Vandivort-Warren, 2012). During this time period, substance abuse expenditures by 
private insurers grew faster than general medical expenditures. Per category of 
treatment type, inpatient, outpatient, or pharmaceutical, 53.0 percent of expenditures 
were reflected in outpatient services, 46.0 percent for inpatient services, and 1.0 percent 
for pharmaceuticals in 2001. In 2009, expenditures on outpatient treatment equaled 43.0 
percent, inpatient 43.0 percent, and pharmaceuticals 29.0 percent. Receipt of substance 
abuse treatment between 2001 and 2009 was an average of 5.1 annual visits for 
outpatient treatment, 7.3 days were the average length of stay for inpatient treatment, 
and number of days supplied for pharmaceuticals increased from 93.0 to 143.3 days 
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annually. On average overall substance abuse expenditures per person annually 
increased 7.8 percent between 2001 and 2009, the annual average rate for outpatient 
treatment increased by 3.4 percent, 5.8 percent for inpatient treatment, and 20.3 percent 
for pharmaceuticals. The result in overall spending on substance abuse treatment 
increased in each category of treatment between 2001 and 2009 (Mark & Vandivort-
Warren, 2012). 
Expenditures 2004 – 2012 
Between 2004 and 2012 per capita spending on substance abuse treatment 
increased 14.7 percent for commercially insured individuals (Thomas Parks, Hodgkin, 
Levit, and Mark, 2016). Comparing this time period to the 2004-2009 and 2009-2012, 
overall health care spending per capita decreased from 6.5 percent to 3.9 percent 
annually, annual spending for substance abuse treatment increased from 10.0 percent to 
22.8 percent. By 2012, substance abuse treatment spending represented less than 1.0 
percent of total health care spending at $32.65 per member per year compared to 
spending on all health care at over $5,000 per member per year. The change in spending 
for substance abuse treatment from 2009 to 2012 reflected a growth in outpatient 
treatment at 63.3 percent, inpatient decreased to 25.4 percent, and prescription drugs 
decreased to 11.3 percent compared to the 2004 to 2009 study period. Although 
expenditures for treatment by private insurers has increased between 2009 to 2012, 
individuals receiving substance abuse treatment remains low compared to a prevalence 
of 8.0 percent of those individuals that meet the criteria for a substance use disorder 
(Thomas Parks et al., 2016). 
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Projected Expenditures Through 2020 
Spending on the treatment of mental and substance use disorders grew at an 
average annual rate of 2.0 percentage points slower than spending on all health from 
1986 through 1998 (Mark, Levit, Yee, and Chow, 2014). From 1998 through 2009 the 
average annual growth rate in spending were similar for mental and substance use 
disorders (6.7 percent) and for all health (6.8 percent). Projections for 2009 through 
2020 is expecting to see a return to slower spending growth rate for the treatment of 
mental and substance use disorders (4.6 percent annual average increase) then the 
previous growth rate of 6.7 percent for the prior 11 years. Concluding that the 
downward trend in the share of all health spending for treatment of mental and 
substance use disorders from 7.4 percent in 2009 to 6.5 percent in 2020 is expected to 
resume. When factoring in ACA legislation, the gaining of coverage both private and 
public will result in a 25.0 percent increase in all spending, by 2020 expenditures will 
be 2.7 percent higher than what would be estimated without the legislation. The ACA 
legislation will provide higher enrollments in Medicaid and private insurers adding 
financial protection to patients, in 2020 the result in higher spending for Medicare will 
result in 7.6 billion and 2.6 billion for private insurers and lower out-of-pocket expenses 
by 1.0 billion. Spending on substance use disorders accounted for 1.0 percent of all 
health spending in 2009 and is projected to remain at this level through 2020, growth in 
spending for substance use disorders is expected to lag behind spending for all health 
care, 5.1 percent and 5.8 percent, which continues the long historical trend (Mark, et al., 
2014). The share of treatment spending on substance use disorders by private insurers is 
expected to pay 0.5 percent of its total expenditures through the projected time-period.  
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Expenditure conclusion 
The data presented by the authors represents a twenty-four-year historical view 
of an eleven-year projection of treatment spending for mental and substance use 
disorders (Mark et al., 2014). The projected spending rates of mental and substance use 
disorder treatment will increase due to expanded coverage and an improving economy. 
The authors predict the historical trend of payment for treatment of mental and 
substance use disorders will continue; the share paid by insurers will increase and the 
out-of-pocket for individuals will decrease. This increase in access to treatment is a 
result of a broader access to treatment; treatment accessed through primary care 
physicians and general hospitals instead of treatment centers specific to mental and 
substance use disorders (Mark et al., 2014).  
Treatment Barriers 
According to Bouchery et al. (2012), 6.5 percent of individuals nationally 
reporting symptoms of a substance use disorder received any type of substance abuse 
treatment resulting in a 93.0 percent or greater treatment gap based on data estimates 
from NSDUH. The research examines the correlation between the type of insurance 
coverage and the receipt of substance abuse treatment. The findings suggest that when 
controlling for demographic characteristics, type of treatment needed, and the 
representations for the severity of substance use disorder, persons with private insurance 
(individual and employer-sponsored) are less likely to receive treatment for a substance 
use disorder than individuals with other types of health insurance (Medicaid, Medicare, 
Champus/VA, and uninsured) (Bouchery et al., 2012).  
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The ways in which private plans impede access to substance abuse treatment are 
through the implementation of managed care utilization controls that create barriers 
(Bouchery et al., 2012). Additional treatment barriers by private plans are through 
limiting service coverage and imposing higher copayments. Persons with private 
insurance most likely have these plans gained through employment; missed work and 
the possibility of stigma relating to substance use disorders may decrease the likelihood 
that individuals meeting the requirements for substance use disorders with seek 
treatment. Bouchery et al. (2012) state findings from a cross-cultural study of the degree 
of stigma and concluded that drug addiction were more stigmatized when compared to 
other health conditions like obesity and dementia. The study concluded that individuals 
with private insurance that meet the requirements for medical necessity were less likely 
to receive treatment, among the group studied; the treatment gap is 70.0 percent 
(Bouchery et al., 2012.  
A majority of private health plans contract their mental health benefits to a third 
party administrator, primarily managed behavioral health care organizations (MHBO) 
(Merrick, Reif, Hiatt, Hodgkin, Horgan, and Ritter, 2012). Employers and health plans 
contract MHBOs to deliver managed mental health services, enrolled patients contact 
the MHBO by phone and then are referred to a specialist based the determined need by 
the MHBO representative (Merrick et al., 2012).  
A survey conducted by Merrick et al. (2012) on the patient’s experience of 
treatment indicated that 18.4 percent of the respondents felt that their specialty 
substance abuse treatment provider had communicated with their primary care 
physician. The survey also concluded that 27.6 percent of the respondents indicated that 
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treatment had stopped sooner then what the patient felt was needed (Merrick et al., 
2012). The authors note a concern for MHBOs in that there is a lack of integration 
between specialty mental health and other medical care, this lack of integration creates a 
treatment barrier (Merrick, et al., 2012). 
An additional barrier to receipt of treatment is through a disconnect of 
understanding by providers on how the MHPAEA affects patients benefits (Edmond, 
Aletraris, Roman, Fields, and Bride, 2016). In a survey conducted that questioned 
administrators of various centers providing substance abuse treatment found that 36.0 
percent of administrators reported a high level of familiarity of MHPAEA (Edmond et 
al., 2016). Administrators that perceived MHPAEA as having no impact on their facility 
equaled 71.0 percent (Edmond et al., 2016). During the time of the survey, the 
facilitates interviewed reported an 18.0 percent increase in admission to a program by 
the privately insured and 15.0 percent reported an increase in insurance coverage 
(Edmond et al., 2016). The authors concluded although the familiarity of MHPAEA 
was low those that perceived a high familiarity of MHPAEA reported that it has had a 
positive impact on the receipt of treatment (Edmond et al., 2016). 
Federal Mental Health Parity vs State Mental Health Parity 
According to CMS (2016) insurance plans subject to ACA guidelines are 
required to offer mental health and substance abuse coverage if the insurer provides any 
type of mental health and substance abuse coverage, insurance plans that provide no 
mental and substance abuse coverage are exempt. Essential mental or substance abuse 
coverage include mental health treatment in the form of psychotherapy, counseling or 
inpatient services. Substance use disorder treatment is required but treatment type is not 
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specified by ACA (2016). Federal parity protection for the treatment of mental or 
substance use disorders include deductibles, copayments, coinsurance, out-of-pocket 
limits, limits of number of days or visits covered, and care management (ACA, 2016). 
As previously mentioned the MHPAEA 2008 and ACA 2010 regulate the ways 
in which private and public insurers deliver substance abuse coverage and treatment. 
Each individual state must comply with these regulations but have the ability to enact 
state parity laws that exceed what is required by the MHPAEA 2008 and ACA 2010. 
Following is a list of types of state parity laws that affect the delivery of mental and 
substance abuse coverage and treatment by private insurers (NAMI, 2010): 
 Comprehensive parity: equal coverage of a wide range of mental health 
conditions and substance use disorders. 
 Broad-based parity: equal coverage of a wide range of mental health conditions 
with some limitations or exemptions. 
 Limited parity: limits equal coverage to a specific list of mental health 
conditions and/or excludes coverage for significant policy groups and/or limits 
equal coverage for specific durations of time, financial limits or cost sharing 
and/or allows plans to opt out of parity due to cost-increase provisions. 
 Mandated if offered: requires mental health coverage equal to other medical 
conditions if the plan offers mental health coverage. 
 Mandated offering: requires plans to offer the mental health coverage that is 
equal to coverage for other medical conditions but the consumer is not required 
to enroll in mental health coverage. 
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 Minimum mandated benefit: mandates minimum mental health coverage that is 
not required to be equal to other medical conditions. 
A study conducted by Dave and Mukerjee (2011) investigated the impact of 
state comprehensive mental health parity on treatment admission rates and cost sharing. 
Comprehensive state parity for mental and substance abuse treatment significantly 
affected the admission of substance abuse treatment, these states reported a 12.58 
percent increase in total treatment admissions. States with limited parity legislation 
reported a 4.7 percent increase. Comprehensive state mental health parity reports that 
self-referrals for substance abuse treatment increase by 23.1 percent; limited state 
mental health parity had no impact on self-referrals. Referrals of admission to treatment 
by healthcare provider or employer indicate a 20.7 percent increase with comprehensive 
parity, limited parity reflected no effect. States that mandate comprehensive parity have 
a higher probability of 3.7 percentage points that the treatment admission by privately 
insured after enacting the law, there is no significant impact of limited parity legislation 
(Dave & Mukerjee, 2011). The combined increase in private and public coverage of 
substance abuse admissions reduces the probability that an admission is uninsured by 
10.0 percentage points among states with comprehensive parity.  
Before MHPAEA, receipt of substance abuse treatment declined for all age 
groups (Mark & Coffey, 2001). However, post MHPAEA research finds mixed results 
on the effectiveness of MHPAEA based on the receipt of substance abuse treatment 
based on age groups. Dave & Mukerjee (2011) also find that age is negatively related to 
substance abuse treatment admissions. Their results indicate that as age increases the 
likelihood of receiving treatment decreases. Conversely, Bouchery et al. (2012) find that 
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children and young adults ages 12 – 21 are approximately half as likely to have received 
any substance abuse disorder treatment compared to 35 – 50 year olds. The 
contradictive results in the literature on the effects of MHPAEA on age is worth further 
examination. 
An examination of the effect of Oregon’s comprehensive parity law on the 
utilization and spending of alcohol and other drug abuse treatment services, independent 
of utilization and spending on treatment of other mental disorders found a statistically 
significant increase in spending on alcohol treatment but not for other drug abuse 
treatment (McConnell, Ridgely, and McCarty, 2012). According to the authors, this 
study is the first to assess the effects of a parity law that restricts non-quantitative 
treatment limitations on the utilization and spending on substance abuse treatment 
services (McConnell et al., 2012). The authors point out that separating alcohol 
treatment and drug abuse treatment is important for identifying the significant 
differences in spending (McConnell et al, 2012). Using the Oregon control group, 
spending on alcohol treatment services increases by 100 percent over the 2005-2006 to 
2007-2008 time period, other studies reflect growth rates closer to 50 percent for a 
similar time period (McConnell et al., 2012). Federal parity has been associated with an 
overall reduction in out-of-pocket spending; Oregon’s parity law was not associated 
with these reductions (McConnell et al., 2012). In Oregon, “medical necessity” is the 
means that insurers use to deny claims for substance abuse treatment; post-parity health 
plans faced greater risk because of the lack of managed care and prior authorization 
(McConnell et al., 2012). Without managed care and prior authorization, insurers have 
more liberty to deny claims based on medical necessity (McConnell et al., 2012). A 
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limitation pointed out by the authors is the period used for the study, a two-year period 
(McConnell et al., 2012). 
An additional study on Oregon’s comprehensive state parity by McConnell, 
Gast, Ridgely, Wallace, Jacuzzi, Rieckmann, McFarland, and McCarty (2012) 
concluded that the comprehensive state parity had no significant increase on mental or 
substance abuse treatment. The study was conducted was over a four year time period in 
which two years prior to Oregon’s state parity was in place and two years after is 
examined (McConnell et al., 2012). The Oregon Insurance Division interpreted the 
MHPAEA as meaning that mental health benefits would have the same expenditure 
consideration as medical/surgical benefits; however, the result of the study reflected no 
substantial increase in expenditures for mental health or substance abuse treatment post-
state parity (McConnell, 2012).  
Chapter 3: Research Question and Hypotheses 
The goal of the current study is to gain a deeper understanding of how federally 
mandated mental health parity and comprehensive state mental health parity laws affect 
the cost of treatment by the insurer and patient. Previous literature suggests that over a 
period of time the cost by private insurers has increased suggesting that the patients’ 
financial responsibility decreased. Two factors affecting the receipt of treatment for 
substance use disorders are federal mandated mental health parity and comprehensive 
state parity. Considering the treatment gap for the receipt of treatment for substance use 
disorders and factoring federal and state parity, logically the receipt of treatment would 
increase in states that have state mental health parity laws that are more comprehensive 
than federal mental health parity. I am comparing 10 states with the federally mandated 
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minimum mental health parity to 10 states with comprehensive state mental health 
parity. To this end, I will test the following research question and hypotheses: 
Research Question 
What impact, if any, does comprehensive state mental health parity laws have 
on the receipt of treatment for substance use disorders compared to states with the 
minimum mandated federal mental health parity? 
Hypotheses 
Hypothesis 1  
 States with comprehensive parity will have a decreased treatment gap 
compared to states without parity. 
Hypothesis 2 
 States with comprehensive parity will have increased expenditures on 
substance abuse treatment. 
Chapter 4: Data and Methods 
Sample 
Data for this study were taken from a sample of twenty states. Ten states with 
comprehensive mental health parity laws (Connecticut, Georgia, Kansas, Maryland, 
Michigan, Minnesota, Missouri, Nevada, New Hampshire, and Vermont) and ten states 
with the minimum mandated mental health parity laws (Arizona, Kentucky, 
Massachusetts, California, Oklahoma, South Dakota, West Virginia, Delaware, Idaho, 
and Illinois) for the year 2014.  
The criteria used to determine which states have comprehensive mental health 
parity laws included alcoholism and drug abuse as a covered illness. In addition to 
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substance use disorders as a covered illness, each comprehensive state applies their laws 
to group and individual health insurance coverage (NAMI, 2010). There are additional 
states besides the 10 previously mentioned but they do not have an inclusion for drug 
and alcohol abuse or only apply their law to certain types of insurers, for that reason 
those states were excluded. 
The criteria used to determine which states have the federally minimum 
mandated parity do not have an inclusion clause for comprehensive treatment for 
substance use disorders (NAMI, 2010). The ten states chosen as the minimum mandated 
mental health parity have no additional state parity laws or if they do, it only applies the 
mental health treatment, not substance use disorders. 
Data gathered from the SAMSHA, Center for Behavioral Health Statistics and 
Quality, National Survey on Drug Use and Health, 2013 and 2014 was used to generate 
the substance use disorder treatment gap for each state individually. The 2015 
SAMSHA Uniform Reporting System (URS) Output Tables was used to generate state 
expenditures per capita total for fiscal year 2014 to control for population. The statistics 
include both mental health expenditures and substance use disorder expenditures 
combined. The year 2014 was chosen for the complete data available post-parity.  As 
stated previously, information from NAMI (2010) was used to categorize states with 
comprehensive state parity laws and states with the federally mandated minimum 
mental health parity laws. 
SAMHSA was established by congress in 1992 in an effort to make substance 
abuse and mental health disorder information, services, and research more available 
(SAMHSA, 2016). SAMHSA is an agency within the U.S. Department of Health and 
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Human Services; the administration promotes public health efforts to improve mental 
health in the United States (SAMHSA, 2016).  
Measures 
Dependent variables 
As stated previously, my first dependent variable, treatment gap, is created from 
information collected by the Substance Abuse and Mental Health Services 
Administration in the 2014 wave of the National Survey of Drug Use and Health. 
Treatment gap is defined as the percentage of individuals who are identified as needing, 
but not receiving, treatment for drug and alcohol dependency and abuse. The treatment 
gap percentage is presented as the ratio of the following information: the total number 
of individuals identified as needing, but not receiving treatment for illicit drug 
dependency and/or abuse is combined with individuals identified as needing, but not 
receiving treatment for alcohol dependency and/or abuse within the last year. This total 
number is then divided by the aggregate of individuals identified as having an illicit 
drug dependency and/or abuse and individuals identified as having alcohol dependency 
and/or abuse in the past year in the sample. 
My second dependent variable, state expenditures is created using information 
obtained from Substance Abuse and Mental Health Services Administration Uniform 
Reporting System, which provides both public and private expenditures per capita for 
treatment of both mental, and substance use disorder treatment measured in U.S. 
Dollars. This data is limited by the fact that state expenditures for substance use 
disorders are not separated from state expenditures for total mental health. As 
mentioned previously, the likelihood that and individual is diagnosed with a substance 
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used disorder has a 40.0 to 65.5 percent chance of also having at least one diagnosis of a 
mental illness (Cosci & Fava, 2011). Therefore state expenditures per capita on all 
mental health treatment is not precise but serves as an adequate proxy for the 
populations studied. An increase in the total state expenditures may be interpreted as an 
increase in both substance abuse disorder and other mental health expenditures.  
Independent variables 
The independent variable is state mental health parity (dummy variable) with 
values 0=no state comprehensive parity and 1=states with comprehensive state parity 
laws. States assigned a 0 value include the following characteristics: no supplemental 
substance use disorder coverage, some states have additional exemptions for the receipt 
of mental health treatment. States assigned a value of 1include the following 
characteristics: mandatory individual and group coverage (some states add Managed 
Health Organizations (HMO)) for mental health disorders, including substance abuse 
treatment must be equal to other covered health conditions. 
Analysis 
To test the hypotheses I rely on comparisons of means using t-test. The t-test is a 
statistical method used to determine whether the difference in means between two 
groups is significant (Stata, 2011). In this case, the two groups of states are defined by 
the existence of state-mandated parity. In this research, I perform two-sample mean-
comparison t-tests to identify if the mean of the first dependent variable, treatment gap 
in states where there is no state mandated parity is significantly different from the mean 
treatment gap in states with state-mandated parity. The results of the t-test will 
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determine if significantly more robust provisions for substance abuse disorder treatment 
results in the reduction of the treatment gap. 
Similarly, I then perform the same two-sample mean-comparison t-tests to 
determine if the mean mental health disorder expenditures in states where there is no 
state-mandated parity is significantly different from the mean substance use 
expenditures in states with state-mandated parity. The results of this t-test will 
determine if significantly more robust provisions for mental health disorder treatment 
results in the increase in substance use disorder expenditures. 
Results 
Appendix A indicates the descriptive statistics for dependent and independent 
variables by age group. The mean treatment gap for ages 12-17 years old is 93.0 
percent, the illicit drug dependency or abuse in thousands is 18.15 thousand, alcohol 
dependency or abuse is 13.55 in Thousands, needed but not received treatment for drugs 
is 17.15 in thousands, and needed but not received treatment for alcohol is 13.1 in 
thousands. 
The mean treatment gap for ages 18-25 years old 92.70 percent, illicit drug 
dependency or abuse is 51.6 in thousands, alcohol dependency or abuse is 93.3 in 
thousands, needed but not received treatment for drugs is 46.75 in thousands, and 
needed but did not receive treatment for alcohol abuse is 88.25 percent in thousands. 
The mean treatment gap for ages 26 years old and older is 92.0 percent, illicit 
drug dependency or abuse is 73.0 in thousands, alcohol dependency or abuse is 239.6 in 
thousands, needed but did not receive treatment for drug abuse is 63.1 in thousands, and 
needed but did not receive treatment for alcohol abuse is 227.5 in thousands. 
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Appendix B shows the results of the two sample t-tests. Initial analysis 
regarding the total substance use disorder treatment gap for states with parity is not 
significantly different from states without comprehensive parity (t= -0.56, p= 0.71). 
What is interesting in these results is that the substance use disorder treatment gap, at 
least while age groups are combined is increased in states with comprehensive parity 
versus states without (as denoted by the negative test statistic) with an actual increase in 
the substance use disorder treatment gap from 92%-93%. The results suggest that 
Hypothesis 1 is not supported. However, with the considerable variation in the ages of 
individuals in the sample from children (minimum of age 12 in the sample) to adults of 
all ages, it seems prudent to further parse the results into specific age groups as defined 
by the dataset. As Appendix B demonstrates, these age groups are 12-17 year olds, 18-
25 year olds, and individuals 26 and up.  
As displayed in the results both age groups containing adults (18-25 and 26 and 
up) continue the trend of an increased substance use disorder treatment gap for states 
with parity versus states without parity (t= -0.81, p= 0.78 and t= -0.97, p= 0.82 
respectively) with average substance use disorder treatment gaps increasing from 92% 
to 94% for individuals aged 18-25 and 91%-93% for individuals aged 26 and up across 
the twenty states in the sample. This result is similar to the results discussed above. 
However, for the 12-17 age group I find that the substance use disorder treatment gap is 
reduced for states with comprehensive parity versus those without parity and this result 
is moderately significant (t= 1.62, p= 0.06) with an average reduction in the substance 
use disorder treatment gap from 97%-89%. This result suggests that in the final 
analysis, Hypothesis 1 finds partial support when age is considered.   
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The results of the t-tests also suggest that state public and private expenditures 
for substance use disorder treatment is significantly higher (t=1.94, p= 0.03) for states 
with comprehensive parity versus those without. As indicated in Appendix B, the 
average cost increased from $100.03 per individual treated for substance use disorder in 
states without comprehensive parity to $158.50 per individual treated in states with 
comprehensive parity. Taken together, the overall results suggest that the shift to 
comprehensive state substance use disorder treatment parity as well as the increased 
expenditures that accompany it are effective in reducing the treatment gap for the 
vulnerable age group of 12-17 years. 
Chapter 5: Discussion and Conclusion 
In the study I performed, twenty states were examined, ten states with 
comprehensive state mental health parity laws and ten states with the federally 
mandated minimum mental health parity. This comparison of states with comprehensive 
mental health parity to states with the federally mandated minimum is to identify if 
comprehensive mental health parity had an impact on the receipt of substance abuse 
treatment and the expenditures per capita within each state. There was not statistical 
significance in the receipt of substance abuse treatment in states with more 
comprehensive mental health parity laws compared to states without comprehensive 
state parity laws. In contrast, there was statistical significance in expenditures for 
mental health treatment in states with comprehensive parity when compared to states 
without comprehensive state parity. This suggests that comprehensive state parity has 
shifted the financial responsibility away from the patient. The statistical insignificance 
in the treatment gap suggests that access to substance abuse treatment has not changed. 
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When choosing my research question and hypotheses I speculated that states 
with more comprehensive state parity laws would have reduced treatment gaps. The 
literature that compared Oregon, a state with comprehensive parity, to other states 
without parity did not find significant difference in the receipt of treatment. The 
literature suggested that not enough time had passed for the state parity laws to affect 
the receipt of treatment rates; the research was performed for the years 2005 to 2008. I 
used a sample year of 2014 to identify if the treatment gap was reduced due to recent 
data availability. The analysis showed that the overall treatment gap was not 
significantly different for parity vs non-parity states. The trend reflects that the 
treatment gap for the receipt of substance use disorders is decreasing but not 
significantly as of 2014. Hypothesis 1 indicated that states with comprehensive mental 
health parity would have a decreased treatment gap; this hypothesis was proven 
partially true but not significant when parsed by age. However, further analysis by age 
groups shows a significant difference in the treatment gap for ages 12-17 years 
suggesting that comprehensive state parity is reducing the treatment gap from 97.0 
percent for states without parity to 93.0 percent for states with parity. In contrast, the 
treatment gap increases for states with parity for ages 18 and older compared to states 
without parity. The overall treatment gap when all age groups are combined is relatively 
the same but there is a slight shift in the reduction of the substance abuse treatment gap 
in states with more comprehensive parity. This suggests that a high-risk group of the 
12-17 year olds are receiving the benefits of comprehensive state parity and solicits 
further research. 
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The literature analyzing the spending on substance abuse treatment between 
1992 and 2012 noted a gradual increase of expenditures for substance use disorders 
nationally. Logically with the implementation of MHPAEA and ACA that requires 
mental health coverage to be equal to other medical coverage an increase in spending 
would occur. The literature did not make a distinction between states with 
comprehensive parity with states having no additional parity provisions. The 
significance with hypothesis 2 is that it made a distinction between states with 
comprehensive parity and states without. By doing this, I was able to identify if the 
increase in mental health expenditures was affected by MHPAEA and ACA only or if 
state comprehensive parity laws were significant on their own. The results on state 
expenditures for mental health per capita for states with comprehensive parity is 
$158.50 per person compared to states without parity resulting in expenditures at 
$100.03 per person. The states with comprehensive parity laws spend significantly more 
per person for mental health treatment than states with the federally mandated 
minimum. This reflects an impact that comprehensive state mental health parity laws 
are having on the expenditures for mental health treatment compared to states only 
complying with MHPAEA and ACA. 
In answering the question what if any impact does comprehensive state mental 
health parity laws have on the receipt of treatment for substance use disorders compared 
to states with the federally mandated minimum the answer is both yes and no within the 
context of this study. The treatment gap rate for states with and without comprehensive 
state parity are not significant except for the age group of 12-17 years. The significant 
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impact is on the receipt of mental health treatment in states with comprehensive parity 
is on state expenditures per capita.  
After reviewing the literature and based on the results of this study, treatment 
barriers continue to be a significant obstacle in the receipt of substance abuse treatment. 
Financial, insurance coverage type, personal obligations, and a lack of understanding on 
how state and federal mental health parity works are the primary barriers to treatment. 
The out-of-pocket expense for substance abuse treatment remains high. This is 
especially true if mental health benefit coverage is managed by a MBHO. The MBHO 
has the option to determine any type of mental health treatment as not medically 
necessary. If this occurs, the total financial responsibility falls on the patient. The 
literature stated that often times missing work is a significant reason why an individual 
would not pursue needed treatment. Most likely, if an individual has private insurance it 
is employer sponsored, an absence at work would be noticed. In addition, a fear of 
stigma attached to a mental health disorder would deter an employee from wanting to 
disclose why they would need time off work if the employer required a specific reason. 
One study indicated that administrators of substance abuse treatment centers were 36.0 
percent of having high familiarity with of MHPAEA and 71.0 percent felt that 
MHPAEA had no impact on the receipt of treatment (Edmond et al., 2016). This would 
affect the coordination of benefits between the insurer and the treatment cost if the 
treatment facility were unclear on how the insurer is required to pay for treatment.  
Education seems to be a key factor in reducing these barriers to treatment 
access. Understanding that substance use disorders are a chronic illness and not simply 
a lifestyle disease would reduce the stigma attached to individuals that suffer from these 
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types of disorders. Treatment for substance use disorders would be considered medical 
necessity instead of a need for behavioral modification through self-control. Members 
of insurance plans need to understand how their benefits work in order to have an 
informed approach to coordinating benefits between the insurer and the treatment 
facility. Employers could focus more on confidential employee assistant programs that 
assist and employee with navigating treatment options based on their type of insurance 
plan. Treatment facilities need to have a better understand of how MHPAEA affects the 
delivery and financial responsibilities between the facility and the patient. The more we 
engage as a society in discussion about mental and substance use disorders the more we 
will realize that this not an individual problem but a societal epidemic. 
Limitations 
The date supplied in this study is a mere snapshot in the processes of 
determining the reasons for the substance abuse treatment gap. I only had access to 
open source data that did not supply as much information as I would need to further 
identify the reasons for the substance abuse treatment gap. The data used to calculate 
the state expenditures per capita combined both mental health treatment and substance 
use disorder expenditures; I was not able to parse the expenditures for substance use 
disorder treatment. Voluntary data with a cost would supply claim information that 
would provide detailed data for the cost of treatment for the three treatment types: 
inpatient, outpatient, and pharmaceutical. These voluntary data sources would further 
parse the data into claims paid by private (Health Managed Organizations (HMO) and 
Preferred Provider Organization (PPO)), public, or self-pay. If this data were readily 
available an in depth research by various categories could have been performed for each 
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state respectively. A benefit of future research is to have more of a time lapse to track 
the changes for state comprehensive parity, MHPAEA, and ACA in relation to the 
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Appendix A: Descriptive Statistics Dependent and Independent 
Variables by Parity and Age Group
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